THE TECHNOLOGY
01Proprietary foundation
A defined active system and a repeatable discovery approach. Fraktion8 is the first commercial focus, with scope to investigate further molecular systems over time.
Investors / Dinetic AG
The next opportunity
is commercial.
Five years of founder-funded research have brought Dinetic to a different starting point: a proprietary active system, a signed licensing contract and an own-brand product ready for production.
THE INVESTMENT CASE
One scientific foundation. Room to grow.
Our ingredient model allows the same technology to reach consumers through multiple partner brands. Formula51 adds an owned route to market. The opportunity is to develop those routes around know-how that stays with Dinetic.
COMMERCIAL VALIDATION
02Partner pathway
A licensing contract signed with a European market leader in topical muscle and joint care.
FORMULA51
03An owned route to market
A Swiss premium skincare brand with Shield ready for production. An additional way to build product value and develop direct market experience.
THE NEXT CONVERSATION
Look closer at Dinetic.
Start with the investor deck.
We welcome investors who bring a long-term perspective, commercial experience or access to relevant markets. Request the deck for a closer look at the company, then discuss the opportunity directly with the founders.
Financing details and selected supporting materials are shared in a direct conversation.
This website provides company information and is not an offer of securities. Development and commercial outcomes remain subject to risk.